CTOs on the Move

Standards Testing Laboratory

www.stllabs.com

 
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stllabs.com
  • 1845 Harsh Ave SE
    Massillon, OH USA 44646
  • Phone: 330.833.8548

Executives

Name Title Contact Details

Similar Companies

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

GenapSys

GenapSys is a company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. GenapSys is headquartered in Redwood City, CA. GenapSys products are provided for Research Use Only. Not for use in diagnostic procedures.

TLC Biopharmaceuticals

TLC Biopharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio, Inc. is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.